JP2024539952A5 - - Google Patents
Info
- Publication number
- JP2024539952A5 JP2024539952A5 JP2024524610A JP2024524610A JP2024539952A5 JP 2024539952 A5 JP2024539952 A5 JP 2024539952A5 JP 2024524610 A JP2024524610 A JP 2024524610A JP 2024524610 A JP2024524610 A JP 2024524610A JP 2024539952 A5 JP2024539952 A5 JP 2024539952A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- weeks
- dota
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163272447P | 2021-10-27 | 2021-10-27 | |
| US63/272,447 | 2021-10-27 | ||
| PCT/IB2022/060331 WO2023073603A1 (en) | 2021-10-27 | 2022-10-27 | Combination therapy of radionuclide complex |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024539952A JP2024539952A (ja) | 2024-10-31 |
| JP2024539952A5 true JP2024539952A5 (cg-RX-API-DMAC7.html) | 2025-11-04 |
Family
ID=84365353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024524610A Pending JP2024539952A (ja) | 2021-10-27 | 2022-10-27 | 放射性核種錯体の組み合わせ療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250387523A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4422701A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024539952A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240093832A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118159304A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022374887A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3234495A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312106A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024004961A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202332473A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023073603A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11129912B1 (en) * | 2020-07-13 | 2021-09-28 | POINT Biopharma Inc. | Radiopharmaceutical and methods |
-
2022
- 2022-10-27 US US18/704,804 patent/US20250387523A1/en active Pending
- 2022-10-27 AU AU2022374887A patent/AU2022374887A1/en active Pending
- 2022-10-27 TW TW111140975A patent/TW202332473A/zh unknown
- 2022-10-27 CN CN202280069041.9A patent/CN118159304A/zh active Pending
- 2022-10-27 JP JP2024524610A patent/JP2024539952A/ja active Pending
- 2022-10-27 MX MX2024004961A patent/MX2024004961A/es unknown
- 2022-10-27 CA CA3234495A patent/CA3234495A1/en active Pending
- 2022-10-27 IL IL312106A patent/IL312106A/en unknown
- 2022-10-27 EP EP22814157.8A patent/EP4422701A1/en active Pending
- 2022-10-27 KR KR1020247016801A patent/KR20240093832A/ko active Pending
- 2022-10-27 WO PCT/IB2022/060331 patent/WO2023073603A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kwekkeboom et al. | Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake | |
| Breeman et al. | The addition of DTPA to [177Lu-DOTA0, Tyr3] octreotate prior to administration reduces rat skeleton uptake of radioactivity | |
| RU2160121C2 (ru) | Агенты для лучевой терапии, содержащие олово-117m | |
| JP2022532187A5 (cg-RX-API-DMAC7.html) | ||
| Picco et al. | Primary hypothyroidism as a consequence of 131‐I‐metaiodobenzylguanidine treatment for children with neuroblastoma | |
| Gao et al. | The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy | |
| US6685913B1 (en) | Lipid soluble radioactive metal chelates for tumor therapy | |
| Khettery et al. | Effect of pentagastrin, histalog, glucagon, secretin, and perchlorate on the gastric handling of 99mTc pertechnetate in mice | |
| Giammarile et al. | Bone pain palliation with 85Sr therapy | |
| AT405906B (de) | Radiomarkierte somatostatin rezeptor-liganden zur diagnose und therapie | |
| JP2025036436A (ja) | 治療用骨剤の使用方法 | |
| Bushnell et al. | Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher™) in patients with diffuse somatostatin receptor positive liver metastases | |
| Pujol et al. | Metastatic phaeochromocytoma with a long-term response after iodine-131 metaiodobenzylguanidine therapy | |
| JP2023522983A (ja) | 前立腺がんの診断および処置のための組成物、キットおよび方法 | |
| RU2024113993A (ru) | Комбинированная терапия на основе радионуклидного комплекса | |
| Kao et al. | Quick diagnosis of hyperthyroidism with semiquantitative 30-minute technetium-99m-methoxy-isobutyl-isonitrile thyroid uptake | |
| Van Soesbergen et al. | Radiosynoviorthesis of the knee: a doubleblind trial of 1 versus 5 mCi Gold-198 | |
| JP2016532652A (ja) | 高純度治療用骨剤 | |
| Changlai et al. | Biodistribution and Dosimetry of 131I in Thyroidectomy Patients Using Semiquantitative γ-Camera Imaging | |
| RU2025124374A (ru) | Способы лечения глиобластомы | |
| Kostial et al. | Efficiency of a composite treatment for mixed fission products in rats | |
| Lin et al. | Reducing renal uptake of111In-DOTATOC: A comparison among various basic amino acids | |
| Kaltsas et al. | Treatment of advanced neuroendocrine tumours with the radiolabelled somatostatin analogue octreotide | |
| KR20240093832A (ko) | 방사성 핵종 복합체의 조합 요법 | |
| RU2025125148A (ru) | Способы лечения рака молочной железы |